Targets › BCL6
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. (UniProt, P41182)
Open in Phaseline: the race on BCL6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | BMS-986458 cereblon-dependent ligand-directed degrader of BCL6 | BCL6 | Phase 1 | Relapsed/Refractory Non-Hodgkin Lymphoma | Oct 2027 |
Relapsed/Refractory Non-Hodgkin Lymphoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.